PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cytokine & Growth Factor Reviews

• Publication date

  2004-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.CYTOGFR.2004.03.002
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth Factor Receptor α and Akt Inactivation

  2004cited by this paper
• The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management

  2004cited by this paper
• Combined inhibition of VEGF‐ and PDGF‐signaling enforces tumor vessel regression by interfering with pericyte‐mediated endothelial cell survival mechanisms

  2004influential reference
• Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate.

  2004cited by this paper
• The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

  2004cited by this paper
• A Potential Oncogenic Activity of Platelet-Derived Growth Factor D in Prostate Cancer Progression

  2004cited by this paper
• Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.

  2004cited by this paper
• Targeting the Platelet-Derived Growth Factor Receptor in Antivascular Therapy for Human Ovarian Carcinoma

  2004cited by this paper
• Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.

  2004cited by this paper
• Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor β Tyrosine Kinase Receptors in Synovial Sarcoma

  2004cited by this paper
• A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

  2003influential reference
• PDGF-D is a potent transforming and angiogenic growth factor

  2003cited by this paper
• Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

  2003influential reference
• Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

  2003cited by this paper
• CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

  2003cited by this paper
• A human brain tumor-derived PDGFR-α deletion mutant is transforming

  2003cited by this paper
• Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

  2003cited by this paper
• Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor α receptor: a new clinical target for STI571/Glivec

  2003cited by this paper
• Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.

  2003cited by this paper
• Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

  2003influential reference
• Genetics of dermatofibrosarcoma protuberans family of tumors: From ring chromosomes to tyrosine kinase inhibitor treatment

  2003cited by this paper
• Complementary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model.

  2003cited by this paper
• Angiogenesis: Tumorigenesis and the angiogenic switch

  2003cited by this paper
• PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

  2003cited by this paper
• PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

  2003cited by this paper
• STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake.

  2003influential reference
• Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers

  2003cited by this paper
• Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.

  2003cited by this paper
• Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors.

  2003cited by this paper
• Novel translocations that disrupt the platelet‐derived growth factor receptor β (PDGFRB) gene in BCR–ABL‐negative chronic myeloproliferative disorders

  2003cited by this paper
• Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta.

  2003cited by this paper
• Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.

  2003cited by this paper
• Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

  2003cited by this paper
• Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report.

  2003cited by this paper
• Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment.

  2003cited by this paper
• The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.

  2002cited by this paper
• Management of malignant gastrointestinal stromal tumours.

  2002cited by this paper
• Tyrosine kinase fusion genes in chronic myeloproliferative diseases

  2002cited by this paper
• Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.

  2002cited by this paper
• Angiogenesis stimulated by PDGF‐CC, a novel member in the PDGF family, involves activation of PDGFR‐aa and ‐ap receptors

  2002cited by this paper
• Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.

  2002cited by this paper
• Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors.

  2002cited by this paper
• Analysis of Mural Cell Recruitment to Tumor Vessels

  2002cited by this paper
• Myeloproliferative Disorders with Translocations of Chromosome 5q31–35: Role of the Platelet-Derived Growth Factor Receptor Beta

  2002cited by this paper
• Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans

  2002cited by this paper
• Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.

  2002cited by this paper
• Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

  2002cited by this paper
• Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene.

  2002cited by this paper
• Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines

  2002cited by this paper
• Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in Dermatofibrosarcoma Protuberans (DP)

  2001cited by this paper
• Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.

  2001cited by this paper
• PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors

  2001cited by this paper
• Malignant glioma: genetics and biology of a grave matter.

  2001cited by this paper
• Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.

  2001cited by this paper
• Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.

  2001cited by this paper
• PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo.

  2001cited by this paper
• Delivery of molecular and cellular medicine to solid tumors.

  2001cited by this paper
• A role of PDGFRα in basal cell carcinoma proliferation

  2001cited by this paper
• Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).

  2000cited by this paper
• Human breast carcinoma desmoplasia is PDGF initiated

  2000cited by this paper
• Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.

  2000cited by this paper
• World Health Organization classification of tumors

  2000cited by this paper
• Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581.

  2000cited by this paper
• The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.

  1999cited by this paper
• Characterization of the chronic myelomonocytic leukemia associated TEL-PDGFβR fusion protein

  1999cited by this paper
• TEL/PDGFβR Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor

  1999cited by this paper
• Mechanism of action and in vivo role of platelet-derived growth factor.

  1999cited by this paper
• Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.

  1999cited by this paper
• Platelet-derived growth factor β receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling

  1999cited by this paper
• Tumorigenic conversion of immortal human keratinocytes through stromal cell activation.

  1998cited by this paper
• Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus.

  1998cited by this paper
• Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans

  1998cited by this paper
• Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.

  1998cited by this paper
• Fusion of Huntingtin Interacting Protein 1 to Platelet-Derived Growth Factor β Receptor (PDGFβR) in Chronic Myelomonocytic Leukemia With t(5;7)(q33;q11.2)

  1998cited by this paper
• The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour

  1997cited by this paper
• Expression in lung carcinomas of platelet-derived growth factor and its receptors.

  1997cited by this paper
• Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution.

  1997cited by this paper
• Deregulation of the platelet-derived growth factor β-chain gene via fusion with collagen gene COL1A1 in dermatof ibrosarcoma protuberans and giant-cell fibroblastoma

  1997cited by this paper
• A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL–PDGFRβ oncoprotein

  1997cited by this paper
• The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways

  1996cited by this paper
• Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas.

  1996cited by this paper
• Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma.

  1996cited by this paper
• Induction of platelet‐derived growth factor A and B chains and over‐expression of their receptors in human pancreatic cancer

  1995cited by this paper
• Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor B chain expression: an immunohistochemical and in situ hybridization study.

  1994cited by this paper
• Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.

  1994cited by this paper
• Three isoforms of platelet-derived growth factors all have the capability to induce angiogenesis in vivo.

  1994cited by this paper
• Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor.

  1994cited by this paper
• Epithelial-stromal interactions in basal cell cancer: the PDGF system.

  1993cited by this paper
• Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells

  1993cited by this paper
• Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer.

  1993cited by this paper
• Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB.

  1993cited by this paper
• Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma.

  1993cited by this paper
• Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas.

  1992cited by this paper
• Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors.

  1992cited by this paper
• Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops.

  1992cited by this paper
• Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin.

  1992cited by this paper
• Platelet-derived growth factor is angiogenic in vivo.

  1992cited by this paper
• Expression of platelet-derived growth factor and its receptors in proliferative disorders of fibroblastic origin.

  1992cited by this paper
• Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors.

  1990cited by this paper
• Generation of fibrosarcomas in vivo by a retrovirus that expresses the normal B chain of platelet-derived growth factor and mimics the alternative splice pattern of the v-sis oncogene.

  1989cited by this paper

• Structural insights into the modulation of PDGF/PDGFR-β complexation by hyaluronan derivatives

  2021cites this paper
• Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells.

  2021cites this paper
• Rhabdomyosarcoma Cells Produce Their Own Extracellular Matrix With Minimal Involvement of Cancer-Associated Fibroblasts: A Preliminary Study

  2021cites this paper
• Long-term survival in a cat with pancreatic adenocarcinoma treated with surgical resection and toceranib phosphate

  2020cites this paper
• Dysregulated PDGFR alpha expression and novel somatic mutations in colorectal cancer: association to RAS wild type status and tumor size

  2020cites this paper
• A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy

  2020cites this paper
• Fibroblast Reprogramming in Gastrointestinal Cancer

  2020cites this paper
• Compound C Inhibits B16-F1 Tumor Growth in a Syngeneic Mouse Model via the Blockage of Cell Cycle Progression and Angiogenesis

  2019cites this paper
• Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC

  2019cites this paper
• Chronic platelet-derived growth factor receptor signaling exerts control over initiation of protein translation in glioma

  2018cites this paper
• Platelet-Derived Growth Factor Receptor (PDGF-R) as the Target for Herbal-Based Anticancer Agents

  2018cites this paper
• PDGF family function and prognostic value in tumor biology.

  2018cites this paper
• Aptamer as Therapeutics for Cancer with Focus on Retinoblastoma

  2018cites this paper
• Receptor Tyrosine Kinases and the Insulin Signaling System

  2017cites this paper
• PDGFRs expression in dogs affected by malignant oral melanomas: correlation with prognosis

  2017cites this paper
• Receptor tyrosine kinase expression and phosphorylation in canine nasal carcinoma.

  2017cites this paper
• Clinical significance of platelet-derived growth factor receptor-β gene expression in stage II/III gastric cancer with S-1 adjuvant chemotherapy.

  2017cites this paper
• Synthesis and evaluation of radioiodinated 1-{2-[5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl]quinolin-8-yl}piperidin-4-amine derivatives for platelet-derived growth factor receptor β (PDGFRβ) imaging.

  2017cites this paper
• Therapeutic Agents That Inhibit Angiogenesis

  2017cites this paper
• Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders.

  2016cites this paper
• [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].

  2016cites this paper
• GASTROINTESTINAL, HEPATOBILIARY, AND PANCREATIC PATHOLOGY mTOR and PDGF Pathway Blockade Inhibits Liver Metastasis of Colorectal Cancer by Modulating the Tumor Microenvironment

  2015cites this paper
• New Discoveries for the Treatment of Lung Cancer and the Role of Small Biopsy Material

  2015cites this paper
• The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth.

  2015cites this paper
• A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors

  2015cites this paper
• Novel endogenous angiogenesis inhibitors and their therapeutic potential

  2015cites this paper
• Glioblastoma multiforme: Pathogenesis and treatment.

  2015cites this paper
• VEGFR2 predicts decreased patients survival in soft tissue sarcomas.

  2015cites this paper
• Tumor vessel up-regulation of INSR revealed by single-cell expression analysis of the tyrosine kinome and phosphatome in human cancers.

  2015cites this paper
• Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer.

  2014cites this paper
• Sunitinib resistance in renal cell carcinoma

  2014cites this paper
• Vascular-targeted agents for the treatment of angiosarcoma

  2014cites this paper
• Tyrosinkinasen in Weichgewebstumoren

  2014cites this paper
• A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

  2014cites this paper
• Molecular Determinants of Cardiac Neovascularization

  2014cites this paper
• Pazopanib-the Latest First-Line Standard of Care Targeted Kinase Inhibitor for the Treatment of Advanced Renal Cell Carcinoma:

  2014cites this paper
• A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors

  2014cites this paper
• Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy.

  2014cites this paper
• Regulation of the anti-tumour immune response by cancer-associated fibroblasts.

  2014cites this paper
• The Effect of Electroacupuncture on Osteosarcoma Tumor Growth and Metastasis: Analysis of Different Treatment Regimens

  2013influential citation
• Genomic compartmentalization of gene families encoding core components of metazoan signaling systems.

  2013cites this paper
• Imatinib as a key inhibitor of the platelet‐derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells

  2013cites this paper
• Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer.

  2013cites this paper
• PDGFs and PDGFRs in canine osteosarcoma: new targets for innovative therapeutic strategies in comparative oncology.

  2013cites this paper
• Redox-regulation of PTPs; mechanisms and impact on PDGFR signaling

  2013cites this paper
• Receptor tyrosine kinase alterations and therapeutic opportunities in squamous cell carcinoma of the lung

  2013cites this paper
• Development of a diagnostic assay for systemic sclerosis

  2013cites this paper
• A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib.

  2013cites this paper
• The major G-quadruplex formed in the human platelet-derived growth factor receptor β promoter adopts a novel broken-strand structure in K+ solution.

  2012cites this paper
• Understanding the Role of Stromal PTEN Regulated miR-101 and miR-130b in Tumor Microenvironment

  2012cites this paper
• Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma

  2012cites this paper
• Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases.

  2012cites this paper
• What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?

  2012cites this paper
• Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.

  2012cites this paper
• Sunitinib malate in solitary fibrous tumor (SFT).

  2012cites this paper
• Role of PDGF in Tumor-Stroma Interactions

  2011cites this paper
• CCL5 Neutralization Restricts Cancer Growth and Potentiates the Targeting of PDGFRβ in Colorectal Carcinoma

  2011cites this paper
• Epigenetics in Pediatric Cancers

  2011cites this paper
• Con C eption , Synthè S e et Évaluation Biologique de dÉ riv ÉS Coumarinique S en tant qu 'agent S anti C an CÉ reux potentiel S

  2011cites this paper
• MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes.

  2011cites this paper
• Small talk in the tumor microenvironment - the contribution of fibroblasts and endothelial cells to the malignant phenotype

  2011influential citation
• Inhibition of prostate cancer using RNA interference-directed knockdown of platelet-derived growth factor receptor.

  2011cites this paper
• INHIBITION OF ANGIOGENESIS BY TARGETING DIFFERENT CELLS: A REVIEW

  2011cites this paper
• Pazopanib: Clinical development of a potent anti-angiogenic drug.

  2011cites this paper
• Models for the Prediction of Receptor Tyrosine Kinase Inhibitory Activity of Substituted 3-Aminoindazole Analogues

  2011cites this paper
• Targeting Signal Transduction Pathways for the Treatment of Kaposi Sarcoma

  2010cites this paper
• Targeted therapies of cancer: angiogenesis inhibition seems not enough.

  2010cites this paper
• Role of platelet-derived growth factors in the testis.

  2010cites this paper
• The transcriptional repression of platelet-derived growth factor receptor-beta by the zinc finger transcription factor ZNF24.

  2010cites this paper
• Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy.

  2010cites this paper
• Angiogenesis in Breast Cancer: Molecular Markers, Therapeutic Targets, Antiangiogenic Therapy & Inhibitors

  2010cites this paper
• Effects of UV-irradiated titania nanoparticles on cell proliferation, cancer metastasis and promotion

  2010cites this paper
• Stromal Cells and Tumor Milieu: PDGF et al.

  2010cites this paper
• Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.

  2010cites this paper
• Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.

  2009cites this paper
• Molecular Therapeutics of Melanoma

  2009cites this paper
• Regulation of Platelet-derived Growth Factor Receptor Function by Integrin-associated Cell Surface Transglutaminase*

  2009cites this paper
• Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

  2009cites this paper
• The pathogenesis of cancer metastasis: Relevance to therapy

  2009cites this paper
• Analyses of Akt and PDGF receptor expression and activation in human tumors

  2009cites this paper
• Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and promitogenic potentials within the distal pulmonary artery wall.

  2009cites this paper
• Genetics and Molecular Biology of Bone and Soft Tissue Tumors

  2009cites this paper
• Peroxiredoxin I, platelet-derived growth factor A, and platelet-derived growth factor receptor alpha are overexpressed in carcinoma ex pleomorphic adenoma: association with malignant transformation.

  2009cites this paper
• Origin of carcinoma associated fibroblasts

  2009cites this paper
• cDNA microarray expression profile in vestibular schwannoma: correlation with clinical and radiological features.

  2009cites this paper
• Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4

  2008cites this paper
• Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy

  2008cites this paper
• Platelet-derived Growth Factor: Impact on Physiological and Tumor Angiogenesis

  2008cites this paper
• The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors

  2008cites this paper
• Targeting the tumor microenvironment (Stroma) for treatment of metastasis

  2008cites this paper
• Genetic and microenvironmental implications in prostate cancer progression and metastasis.

  2008cites this paper
• Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer.

  2008cites this paper
• EXPRESSIÓ DE KIT I PDGFR EN TUMORS DE CÈL·LULES RENALS "DISCUSSIÓ DEL SEU PAPER COM A POSSIBLES DIANES TERAPÈUTIQUES"

  2008cites this paper
• Angiogenesis as a target for the treatment of cancer

  2008cites this paper
• Cancer as an overhealing wound: an old hypothesis revisited

  2008cites this paper
• Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects

  2008cites this paper
• Role of platelet-derived growth factors in physiology and medicine.

  2008cites this paper
• Molecular Signaling Pathways in Pancreatic Cancer

  2008cites this paper
• Challenges of antiangiogenic therapy of tumors

  2008cites this paper
• New developments in multitargeted therapy for patients with solid tumours.

  2008cites this paper